Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that it has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its combination of Lynparza (olaparib) and Imfinzi (durvalumab) in treating advanced or recurrent endometrial cancer. The recommendation covers patients with both mismatch repair proficient (pMMR) and deficient (dMMR) disease.

Based on Phase III DUO-E trial data, the recommendation underscores significant improvements in progression-free survival compared to chemotherapy alone. For pMMR patients, the Lynparza and Imfinzi combination demonstrated a 43% risk reduction in disease progression or death. Similarly, for dMMR patients, Imfinzi alone showed a 58% reduction.

Endometrial cancer is a significant health burden in Europe, with a high unmet need for effective treatments, particularly for pMMR disease. The safety profiles of the regimens were manageable and consistent with known agent profiles.

The approval recommendation marks a significant advancement in AstraZeneca's oncology portfolio strategy, reinforcing its commitment to delivering innovative treatments across diverse cancer types and patient populations.